Market Dynamics: The global market for invasive aspergillosis is projected to demonstrate a consistent growth in revenue with a Compound Annual Growth Rate (CAGR) during the forecast period. This growth in revenue is primarily attributed to factors such as the increasing incidence of aspergillosis and the demand for effective treatments for the disease.
Key Market Trends and Innovations: The ability of anticancer and immunosuppressive medications to affect the immune system’s ability to combat invasive mold infections is gaining importance alongside antifungal treatments. This highlights the need for individualized approaches to prevention and treatment of invasive mold infections. For instance, Astellas Pharma Global Development, Inc. is conducting Phase 2 clinical trials to evaluate the effectiveness of isavuconazonium sulfate in the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric patients.
Organic and Inorganic Strategies Adopted: In May 2022, Shionogi & Co., Ltd. and F2G Ltd. established a strategic agreement to develop and commercialize olorofim, a novel antifungal drug for invasive fungal diseases, across Europe and Asia. In May 2019, AVIR Pharma Inc. announced the availability of Cresemba (isavuconazole, as isavuconazonium sulfate), an antifungal approved for treating invasive aspergillosis or invasive mucormycosis in adult patients, in Canada. In January 2019, Mayne Pharma Group Limited launched TOLSURA (SUBA-itraconazole) 65 mg capsules in the U.S. TOLSURA is a novel itraconazole formulation used to treat systemic fungal infections like aspergillosis, blastomycosis, and histoplasmosis.
Get a sample copy of the Invasive Aspergillosis Treatment Market report: https://www.reportsanddata.com/download-free-sample/5853
The specific symptoms of invasive aspergillosis can vary depending on the organs affected. Individuals afflicted with this condition often experience symptoms such as fever, chills, headaches, cough with blood (hemoptysis) or sputum production, shortness of breath (dyspnea), and chest pain.
Factors Contributing to Revenue Growth in the Market: Drivers: The rising prevalence of fungal and nosocomial infections is a key driver of revenue growth in the global invasive aspergillosis treatment market. Additionally, efforts by both public and private organizations to increase awareness of various fungal infections are expected to fuel revenue growth in the invasive aspergillosis market. Moreover, the increasing incidence of fungal diseases such as aspergillosis is anticipated to drive revenue growth in the treatment market for invasive aspergillosis during the forecast period.
Restraints: The stringent and time-consuming drug approval process for treatment medications is expected to hinder revenue growth in the global invasive aspergillosis treatment market. Further limitations to revenue growth are posed by drug recalls and the discontinuation of clinical trials. For instance, in December 2018, Astellas Pharma China, Inc. terminated a post-marketing study evaluating the effectiveness and tolerability of Micafungin treatment for invasive aspergillosis patients.
Opportunities: The invasive aspergillosis treatment market is undergoing significant research and development, leading to the introduction of numerous new products. This motivates manufacturers to meet the increasing demand for effective and efficient treatment options.
Companies are dedicating substantial research efforts to develop novel drug regimens, supported by significant financial investments. This has contributed to the growth of revenue in the market. A comprehensive product pipeline for the treatment of chronic aspergillosis is expected to drive revenue growth in the global chronic aspergillosis treatment market during the forecast period. For example, in May 2022, Merck Sharp & Dohme LLC reported entering Phase 2 clinical trials to assess the safety and efficacy of Posaconazole (POS), available in intravenous (IV) and oral formulations, in pediatric patients aged 2 to 18 years with invasive aspergillosis (IA).
Geographic Market Scenario: Largest Market Share: North America is projected to hold the largest share of revenue during the forecast period. This is attributed to the increasing prevalence of infectious diseases. The rise in disease prevalence has created a sense of urgency for clinical treatment and has also accelerated the development of new drugs with fast-track approvals from the U.S. Food and Drug Administration (FDA).
Fastest Growing Region: Asia Pacific is expected to witness a significant CAGR in revenue over the forecast period. This growth is attributed to the region’s substantial target population, increasing disposable income, the availability of drugs, and unmet clinical needs. Consequently, global players are focusing on increased research and development investments and offering branded drugs at more affordable prices in the region.
Japan, in particular, holds a significant portion of the regional market due to rising medical costs and expanded insurance coverage. The high demand for effective treatment of invasive aspergillosis represents a significant market opportunity in this region, contributing to rapid growth in the global invasive treatment market during the forecast period.
Major Companies in the Market Include:
- Astellas Pharma Inc.
- Abbott Laboratories
- Pfizer Inc.
- Mylan N.V.
- Glenmark Pharmaceuticals
- Merck & Co., Inc.
- Mayne Pharma Group Limited
- GSK plc
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Basilea Pharmaceutica Ltd.
- AstraZeneca plc
- AVIR Pharma Inc.
- Shionogi & Co., Ltd.
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Merck Sharp & Dohme LLC
Explore Trending Reports:
Transcatheter Pulmonary Valve (TPV) Therapy Market-https://www.globenewswire.com/news-release/2019/02/28/1744573/0/en/Transcatheter-Pulmonary-Valve-TPV-Therapy-Market-To-Reach-66-4-Billion-By-2026-Reports-And-Data.html
Antifungal Drugs Market-https://www.globenewswire.com/news-release/2019/05/13/1822689/0/en/Global-Antifungal-Drugs-Market-To-Reach-USD-13-03-Billion-By-2026-Reports-And-Data.html
Sacral Neuromodulation Market-https://www.globenewswire.com/news-release/2019/06/10/1866396/0/en/Sacral-Neuromodulation-Market-To-Reach-USD-3153-4-Million-By-2026-Reports-And-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5853
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release